Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Loss of joint space width and of cartilage volume at 36 months in treatment groups in patients with meniscal extrusion

From: Meniscal extrusion promotes knee osteoarthritis structural progression: protective effect of strontium ranelate treatment in a phase III clinical trial

  SrRan 1 g/day SrRan 2 g/day Placebo P -value Placebo versus
SrRan 1 g/day
Placebo versus
SrRan 2 g/day
n = 19 n = 15 n = 26 P -value P -value
Joint space width loss       
  mm -0.46 ± 0.45 -0.41 ± 0.42 -0.76 ± 0.67 0.085*   
  % -18.54 ± 19.69 -14.67 ± 15.69 -23.24 ± 19.23 0.228*   
MRI (%)       
Global knee -7.66 ± 2.10 -6.67 ± 2.56 -8.02 ± 3.28 0.351*   
  Femur -7.70 ± 2.66 -6.98 ± 4.26 -7.28 ± 2.91 0.809*   
  Plateau -7.61 ± 3.79 -5.74 ± 3.54 -10.01 ± 5.79 0.003* 0.070** 0.007**
Medial compartment -10.29 ± 3.68 -9.14 ± 3.27 -10.40 ± 4.23 0.119*   
  Medial femur -11.17 ± 4.25 -10.72 ± 5.36 -10.89 ± 3.19 0.290*   
  Medial plateau -8.13 ± 5.98 -4.90 ± 5.19 -9.07 ± 8.74 0.048* 0.708** 0.081**
  1. Results for cartilage volume loss are percentage (%) of change expressed as mean ± SD. *P-values assessed using the Kruskal-Wallis test; P-values assessed using the **Mann-Whitney test with Bonferroni adjustment. Statistically significant P-values are in bold. SrRan, strontium ranelate; n, number of participants; MRI, magnetic resonance imaging.